MSTN and nemaline myopathy: Myostatin inhibition treatment using mRK35 (Pfizer, New York, NY, USA) was investigated in the TgACTA1D286G mouse model of nemaline myopathy and was found to be efficacious in normalising body weight, myofibre force, and grip strength63.